WuXi Biologics Financials

WXXWY Stock  USD 3.59  0.12  3.46%   
Please harness analysis of WuXi Biologics fundamentals to determine if markets are correctly pricing the firm. We are able to interpolate and break down thirty available indicators for WuXi Biologics, which can be compared to its rivals. To ensure the equity is not overpriced, please check out all WuXi Biologics financials, including its cash and equivalents, cash flow from operations, total asset, as well as the relationship between the debt to equity and number of employees . Given that WuXi Biologics has a price to earning of 97.10 X, we strongly advise you to confirm WuXi Biologics prevalent market performance to make sure the company can sustain itself down the road. The stock experiences an expected bullish sentiment for its category. Check odds of WuXi Biologics to be traded at $4.31 in 90 days.
With this module, you can analyze WuXi financials for your investing period. You should be able to track the changes in WuXi Biologics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past WuXi Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of WuXi Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in WuXi Biologics' assets may result in an increase in income on the income statement.
Evaluating WuXi Biologics' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of WuXi Biologics' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the WuXi Biologics' relative financial performance

Chance Of Distress

Less than 9

 
100  
 
Zero
Low
WuXi Biologics has less than 9 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for WuXi Biologics pink sheet is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, WuXi Biologics' odds of distress score SHOULD NOT be confused with the real chance of WuXi Biologics filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as WuXi is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include WuXi Biologics' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in WuXi Biologics' official financial statements usually reflect WuXi Biologics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of WuXi Biologics. For example, before you start analyzing numbers published by WuXi accountants, it's critical to develop an understanding of what WuXi Biologics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of WuXi Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, WuXi Biologics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in WuXi Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of WuXi Biologics. Please utilize our Beneish M Score to check the likelihood of WuXi Biologics' management manipulating its earnings.

WuXi Biologics Company Summary

WuXi Biologics competes with Novo Nordisk, Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, and CSL. WuXi Biologics Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the Peoples Republic of China, North America, Europe, and internationally. The company was incorporated in 2014 and is headquartered in Wuxi, China. Wuxi Biologics is traded on OTC Exchange in the United States.
InstrumentUSA Pink Sheet View All
ExchangePINK Exchange
Business AddressNo 108, Meiliang
SectorHealthcare
IndustryBiotechnology
BenchmarkNYSE Composite
Websitewww.wuxibiologics.com
CurrencyUSD - US Dollar
You should never invest in WuXi Biologics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of WuXi Pink Sheet, because this is throwing your money away. Analyzing the key information contained in WuXi Biologics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

WuXi Biologics Key Financial Ratios

Generally speaking, WuXi Biologics' financial ratios allow both analysts and investors to convert raw data from WuXi Biologics' financial statements into concise, actionable information that can be used to evaluate the performance of WuXi Biologics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that WuXi Biologics reports annually and quarterly.

WuXi Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining WuXi Biologics's current stock value. Our valuation model uses many indicators to compare WuXi Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across WuXi Biologics competition to find correlations between indicators driving WuXi Biologics's intrinsic value. More Info.
WuXi Biologics is rated first in current ratio category among related companies. It is rated third in revenue category among related companies totaling about  4,473,934,783  of Revenue per Current Ratio. . Comparative valuation analysis is a catch-all model that can be used if you cannot value WuXi Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for WuXi Biologics' Pink Sheet . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the WuXi Biologics' earnings, one of the primary drivers of an investment's value.

WuXi Biologics Systematic Risk

WuXi Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. WuXi Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on WuXi Biologics correlated with the market. If Beta is less than 0 WuXi Biologics generally moves in the opposite direction as compared to the market. If WuXi Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one WuXi Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of WuXi Biologics is generally in the same direction as the market. If Beta > 1 WuXi Biologics moves generally in the same direction as, but more than the movement of the benchmark.

About WuXi Biologics Financials

What exactly are WuXi Biologics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include WuXi Biologics' income statement, its balance sheet, and the statement of cash flows. Potential WuXi Biologics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although WuXi Biologics investors may use each financial statement separately, they are all related. The changes in WuXi Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on WuXi Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze WuXi Biologics Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as WuXi Biologics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of WuXi has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if WuXi Biologics' financials are consistent with your investment objective using the following steps:
  • Review WuXi Biologics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand WuXi Biologics' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare WuXi Biologics' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if WuXi Biologics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

WuXi Biologics March 29, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of WuXi Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of WuXi Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of WuXi Biologics based on widely used predictive technical indicators. In general, we focus on analyzing WuXi Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build WuXi Biologics's daily price indicators and compare them against related drivers.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in WuXi Biologics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for WuXi Pink Sheet analysis

When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Please note, there is a significant difference between WuXi Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if WuXi Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, WuXi Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.